LGALS3 and hypertensive disorder: Six genes, including AMOT and PLEKHH3, were up-regulated (Table 3) in the treatment-naïve OSA patients versus PS subjects and further up-regulated in OSA patients with EDS as compared to that in those without EDS.LGALS3(fold change 2.23, p = 0.003) and metallopeptidase inhibitor 2 (TIMP2; fold change 4.44, p = 0.043) were up-regulated in the treatment-naïve OSA patients versus PS subjects, and further up-regulated in OSA patients with hypertension(LGALS3: fold change 4.37, p = 0.044; TIMP2; fold change 5.42, p = 0.018) as compared to that in those without hypertension (Table 3).